The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Ocular delivery of proteins and peptides: Challenges and novel formulation approaches
Open accessAbstract
The impact of proteins and peptides on the treatment of various conditions including ocular diseases over the past few decades has been advanced by substantial breakthroughs in structural biochemistry, genetic engineering, formulation and delivery approaches. Formulation and delivery of proteins and peptides, such as monoclonal antibodies, aptamers, recombinant proteins and peptides to ocular tissues poses significant challenges owing to their large size, poor permeation and susceptibility to degradation. A wide range of advanced drug delivery systems including polymeric controlled release systems, cell‐based delivery and nanowafers are being exploited to overcome the challenges of frequent administration to ocular tissues. The next generation systems integrated with new delivery technologies are anticipated to generate improved efficacy and safety through the expansion of the therapeutic target space. This review will highlight recent advances in formulation and delivery strategies of protein and peptide based biopharmaceuticals. We will also describe the current state of proteins and peptides based ocular therapy and future therapeutic opportunities. Graphical abstract Figure. No Caption available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702
Biopharmaceutical benchmarks 2014
Walsh, G. (2014) · Nature Biotechnology · doi:10.1038/nbt.3040 · Cited by 1,008
Challenges and obstacles of ocular pharmacokinetics and drug delivery
Urtti, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.027 · Cited by 1,003
Corneal structure and transparency
Meek, K. M., & Knupp, C. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.07.001 · Cited by 853
Approaches for enhancing oral bioavailability of peptides and proteins
Renukuntla, J., Vadlapudi, A. D., Patel, A., Boddu, S. H. S., & Mitra, A. K. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.02.030 · Cited by 681 · cited 1×
“Rather active transport which involves binding to specific receptor, pinocytocis or endocytosis are the major mechanisms responsible for absorption [42,43].”
BackgroundSelf-citationMandal, A., Bisht, R., Rupenthal, I. D., & Mitra, A. K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.012 · Cited by 481 · cited 1×
“There are fewer examples of micelles for delivering biopharmaceuticals to ocular tissues which are currently under development [181].”
BackgroundSelf-citationIssues in long-term protein delivery using biodegradable microparticles
Ye, M., Kim, S., & Park, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.05.011 · Cited by 386 · cited 1×
“The encapsulation process for proteins and peptides is more challenging because these macromolecules often lose their structure and biological activity upon interaction with polymeric materials and biological fluids [140].”
BackgroundPEG-modified biopharmaceuticals
Bailon, P., & Won, C.-Y. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240802650568 · Cited by 366
Suprachoroidal drug delivery to the back of the eye using hollow microneedles
Patel, S. R., Lin, A. S. P., Edelhauser, H. F., & Prausnitz, M. R. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0271-y · Cited by 330 · cited 1×
“Although, microcannula suprachoroidal injections have shown not to sustain the release of bevacizumab as superiorly as intravitreal injections post oneweek [128],MNshave demonstrated the potential in delivering bevacizumab (100 μl) to the SCSwithout any serious adverse effects as noted in Phase I clinical trials [129,…”
BackgroundFrost, G. I. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.4.427 · Cited by 323 · cited 1×
“It is currently undergoing Phase I clinical trial for multiple myeloma (NCT02519452) [81].”
Background
Cited by
Recent progress in drug delivery
Li, C., Wang, J., Wang, Y., Gao, H., Wei, G., Huang, Y., Yu, H., Gan, Y., Wang, Y., Mei, L., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.003 · Cited by 818
Ocular drug delivery: present innovations and future challenges
Gote, V., Sikder, S., Sicotte, J., & Pal, D. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.256933 · Cited by 441
Self-citationHydrogel-based commercial products for biomedical applications: A review
Cascone, S., & Lamberti, G. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118803 · Cited by 421
Than, A., Liu, C., Chang, H., Duong, P. K., Cheung, C. M. G., Xu, C., Wang, X., & Chen, P. (2018) · Nature Communications · doi:10.1038/s41467-018-06981-w · Cited by 345
Designing antibodies as therapeutics
Carter, P. J., & Rajpal, A. (2022) · Cell · doi:10.1016/j.cell.2022.05.029 · Cited by 267
Hyaluronic acid in ocular drug delivery
Zhang, X., Wei, D., Xu, Y., & Zhu, Q. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.118006 · Cited by 196
Anti-oxidative and anti-inflammatory micelles: break the dry eye vicious cycle
Li, S., Lu, Z., Huang, Y., Wang, Y., Jin, Q., Shentu, X., Ye, J., Ji, J., Yao, K., & Han, H. (2022) · Advanced Science · doi:10.1002/advs.202200435 · Cited by 174
Zhao, X., Seah, I., Xue, K., Wong, W., Tan, Q. S. W., Ma, X., Lin, Q., Lim, J. Y. C., Liu, Z., Parikh, B. H., et al. (2022) · Advanced Materials · doi:10.1002/adma.202108360 · Cited by 84
Self-assembling tacrolimus nanomicelles for retinal drug delivery
Gote, V., Mandal, A., Alshamrani, M., & Pal, D. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111072 · Cited by 39
Self-citationSalman, A., Kantor, A., McClements, M. E., Marfany, G., Trigueros, S., & MacLaren, R. E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091842 · Cited by 37
Su, Y., Fan, X., & Pang, Y. (2023) · Biomaterials Science · doi:10.1039/d3bm00505d · Cited by 33
Fan, X., Jiang, K., Geng, F., Lu, W., & Wei, G. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114864 · Cited by 33
Main methods and tools for peptide development based on protein-protein interactions (PPIs)
Baeza, J., Bedoya, M., Cruz, P., Ojeda, P., Adasme-Carreño, F., Cerda, O., & González, W. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151623 · Cited by 8
Metadata
- Authors
- Mandal, A., Pal, D., Agrahari, V., Trinh, H. M., Joseph, M., & Mitra, A. K.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 126
- Pages
- 67-95
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2783573752
- Cited by
- 225
- References
- 21
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.